Clinical Trial Update: Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating six months of HER2-targeted therapy in patients with HER2-positive early-stage breast cancer who achieved pathologica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Breast Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING